Thanks. I know that.
Obviously this, while true, doesn't make any sense at all:
"The 7.20.15 pr is only found if you don't filter for 2015."
The question is "Why?"
Press Releases
Year: 2015
Category: All Categories
November 23, 2015
Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
November 16, 2015
Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer
November 11, 2015
Cellceutix Completes Cohort in Kevetrin Clinical Trial; Cheers to Ocata Therapeutics
November 10, 2015
Cellceutix Files Form 10-Q Quarter Ended September 30, 2015
October 30, 2015
Cellceutix Provides Brilacidin Update; New Class of Antibiotics to Enter Phase 3
October 26, 2015
Cellceutix to Request Meeting with FDA for Phase 2 Ovarian Cancer Study; Company’s First-in-Human Study Defines the Pharmocokinetic Profile of Kevetrin
October 21, 2015
Cellceutix Announces Date for Annual Meeting
October 13, 2015
Cellceutix Provides Update on its Phase 3 Preparations for ABSSSI
October 02, 2015
Cellceutix Retains Ashcroft Law Firm, Seeks Withdrawal of Complaint
September 30, 2015
Enrollment Approximately 50 Percent Complete in Cellceutix Phase 2 Clinical Trial of Prurisol for Chronic Plaque Psoriasis
September 16, 2015
Cellceutix Announces Brilacidin Data to be Presented by ICPD at The Joint 55th Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC)
September 08, 2015
Cellceutix Plans for Phase 2 Clinical Trial in Ovarian Cancer
September 08, 2015
Cellceutix Announces Filing of its Annual Report on Form 10-K
August 23, 2015
Cellceutix Requesting Meeting with FDA on Kevetrin for Pediatric Retinoblastoma
August 20, 2015
Cellceutix’s Clinical Trial of Anti-Cancer Agent Kevetrin Meeting its Goals, Approaching End of Trial
August 11, 2015
Cellceutix’s Kevetrin and Thymoma—a Rare Cancer
August 10, 2015
Cellceutix: Thank You
August 07, 2015
Cellceutix Provides Insights to Its Four Clinical Trials for the Treatment of ABSSSI (Completed Phase 2)...
August 06, 2015
Cellceutix Commences Phase 2 Trial of Prurisol as New Treatment for Psoriasis
August 03, 2015
Cellceutix Announces Ongoing Enrollment of Phase 2 Trial of Brilacidin for Oral Mucositis
July 15, 2015
Cellceutix’s Kevetrin Receives FDA Orphan Drug Designation for the Treatment of Ovarian Cancer
June 08, 2015
Cellceutix Provides Update on Uplist Application
June 03, 2015
Cellceutix Poster at ASCO 2015 Attracts Attention of Industry and Academia
June 01, 2015
Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis Expanding to Additional Centers
May 28, 2015
Cellceutix to Present Poster on Kevetrin, a Novel p53 Targeted Therapy for Solid Tumors, at American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2015
Enrollment Begins in Cellceutix Phase 2 Trial of Brilacidin-OM to Prevent Oral Mucositis in Patients Undergoing Chemoradiation
May 22, 2015
IRB Approves Additional Enrollment in Cellceutix’s Clinical Trial of New Cancer Drug Candidate for Solid Tumors
May 13, 2015
Cellceutix Reports Results for Quarter Ended March 31, 2015; Enrollment for Oral Mucositis Studies to Begin this Month
April 27, 2015
Cellceutix Selects Independent Directors and Committee Members
April 21, 2015
Cellceutix Provides Corporate Update
April 13, 2015
Cellceutix PIND Meeting Scheduled with FDA for Hidradenitis Suppurativa
April 01, 2015
Cellceutix Enters into $30 Million Common Stock Purchase Agreement
March 24, 2015
Tenth Cohort Completed in Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin. No Adverse Events Reported
March 16, 2015
Cellceutix Advancing Treatment for Hidradenitis Suppurativa, Pre-IND Meeting Request to Food and Drug Administration
March 02, 2015
Cellceutix to Expand its Skin Product Pipeline
January 26, 2015
Cellceutix Plans Clinical Trial in Patients with Ulcerative Proctitis
January 22, 2015
Cellceutix Phase 2b Clinical Trial of Brilacidin Accepted for Oral Presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
January 20, 2015
Cellceutix Reports Spleen Lesion ‘Disappears’ in Patient with Metastatic Stage 4 Ovarian Cancer in Clinical Trial of Anti-Cancer Drug Kevetrin
January 12, 2015
Cellceutix Invites All to Attend Company’s Live Webcast of Presentation at Biotech Showcase 2015 Today at 2:00 PM PT
January 05, 2015
Cellceutix Releases Confidence Interval Statistics Showing Clinical Success Rates for Brilacidin in Treatment of ABSSSI
